EVOK
Evoke Pharma IncCompany Information
- Company Name
- Evoke Pharma Inc
- CIK
- CIK0001403708
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- EVOK: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- EVOK
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-11-06
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 9,041
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 590,713
- Shares outstanding
- 2,557,408
- Ownership
- 23.10%
Earnings Market Reaction
- Filing date
- 2025-11-13
- Price on filing date
- —
- 1-month reaction
- 2.25%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 12 | 12 | 13 | 14 | 11 | 9 | 10 | 5 | 6 | 7 | 8 | 10 | ||||||
| Receivables Net Current | 3 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Prepaid Expense Current | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | ||||||
| Inventory Net | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 16 | 16 | 16 | 17 | 14 | 12 | 12 | 7 | 8 | 9 | 10 | 12 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Deferred Costs | - | - | - | 0 | 0 | - | - | 0 | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Assets | 16 | 16 | 16 | 18 | 14 | 12 | 12 | 7 | 8 | 9 | 10 | 12 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Long Term Notes Payable | - | - | - | - | - | - | - | 5 | 5 | 5 | 5 | 5 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 4 | 4 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Employee Related Liabilities Current | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | - | - | - | ||||||
| Interest Payable Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | - | - | - | - | ||||||
| Accounts Payable And Accrued Liabilities Noncurrent | - | - | - | - | - | - | - | 2 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Noncurrent | - | - | - | - | - | - | - | 7 | 6 | 6 | 6 | 6 | ||||||
| Liabilities Current | 12 | 12 | 10 | 10 | 10 | 9 | 9 | 10 | 2 | 2 | 2 | 2 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 12 | 12 | 11 | 10 | 10 | 9 | 9 | 10 | 9 | 8 | 8 | 8 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | - | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 136 | 136 | 136 | 136 | 132 | 129 | 129 | 121 | 121 | 120 | 120 | 120 | ||||||
| Retained Earnings Accumulated Deficit | -133 | -132 | -130 | -129 | -128 | -126 | -125 | -123 | -121 | -120 | -118 | -116 | ||||||
| Stockholders Equity | 3 | 4 | 6 | 7 | 4 | 3 | 3 | -3 | -1 | 1 | 2 | 4 | ||||||
| Liabilities And Stockholders Equity | 16 | 16 | 16 | 18 | 14 | 12 | 12 | 7 | 8 | 9 | 10 | 12 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Common Stock Shares Issued | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEvoke Pharma Inc (EVOK) — SEC Financial Statements & Analysis
Evoke Pharma Inc (EVOK) is a pharmaceutical preparations company, incorporated in DE. Evoke Pharma Inc trades on Nasdaq as: EVOK. Evoke Pharma Inc (EVOK)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-13. Based on that filing, On profitability, Evoke Pharma Inc posts a gross margin of 103.47%, an operating margin of -35.99%, a net margin of -36.23%, a Return on Equity (ROE) of -134.88%, a Return on Assets (ROA) of -35.07%, and a Return on Invested Capital (ROIC) of -715.96%. Per share, it reports EPS of $-2.04, diluted EPS of $-2.04, free cash flow per share of $-1.30, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 67.40% year-over-year, net income growth of -14.98% year-over-year, and EPS growth of -53.46% year-over-year. On the balance sheet, it maintains a current ratio of 1.27x, a quick ratio of 1.21x, working capital of $3.30M, a debt-to-equity ratio of 3.65x, a debt ratio of 0.79, an interest coverage ratio of -10.38x, free cash flow of $-3.32M (TTM), and net debt of $-6.58M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-2.04
- ROE TTM
- -134.88%
- ROA TTM
- -35.07%
- Debt To Equity
- 3.65x
- Free Cash Flow TTM
- $-3.32M
- Net Revenue TTM Growth 1Y
- 67.40%
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Evoke Pharma Inc in?
Evoke Pharma Inc (EVOK) operates in the Pharmaceutical Preparations industry.
What exchange does EVOK trade on?
Evoke Pharma Inc (EVOK) trades on the Nasdaq.
Where is Evoke Pharma Inc incorporated?
Evoke Pharma Inc is incorporated in DE.
When was Evoke Pharma Inc (EVOK)'s most recent SEC filing?
Evoke Pharma Inc (EVOK)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-13.
What is EVOK's EPS (earnings per share)?
Evoke Pharma Inc (EVOK)'s trailing twelve month EPS is $-2.04 as of 2025-09-30.
What is EVOK's ROE (return on equity)?
Evoke Pharma Inc (EVOK)'s trailing twelve month Return on Equity (ROE) is -134.88% as of 2025-09-30.
What is EVOK's ROA (return on assets)?
Evoke Pharma Inc (EVOK)'s trailing twelve month Return on Assets (ROA) is -35.07% as of 2025-09-30.
What is EVOK's ROIC (return on invested capital)?
Evoke Pharma Inc (EVOK)'s trailing twelve month Return on Invested Capital (ROIC) is -715.96% as of 2023-12-31.